慢性乙型肝炎病毒治疗的争议：乙型肝炎病毒 DNA 和表面抗原滴度的作用。

Controversies in Treating Chronic Hepatitis B virus: The Role of Hepatitis B Virus DNA and Surface Antigen Titer.

机构信息

Division of Gastroenterology and Hepatology, Department of Medicine, National University Hospital, University Medicine Cluster, National University Health System, 1E, Kent Ridge Road, NUHS Tower Block Level 10, Singapore 119228, Singapore; Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore. Electronic address: https://twitter.com/DrHuangDQ.

出版信息

Clin Liver Dis. 2021 Nov;25(4):763-784. doi: 10.1016/j.cld.2021.06.005. Epub 2021 Jul 30.

DOI:10.1016/j.cld.2021.06.005

PMID:34593152

Abstract

Controversial areas in chronic hepatitis B (CHB) are those where there is uncertainty, or differences of opinion in management, or where evidence may be insufficient. Areas of controversy include whether patients with high viral load but normal liver function tests should be treated to prevent hepatocellular carcinoma (HCC) or liver disease progression to cirrhosis. Another area is whether quantitative hepatitis B surface antigen (qHBsAg) can be used to better characterize phases of CHB and prognosticate. Finally, the utility of qHBsAg in the management of patients on antiviral therapy such as interferon and nucleoside analogues could improve management practices.

摘要

慢性乙型肝炎（CHB）的争议领域是指存在不确定性、管理意见分歧或证据可能不足的领域。争议领域包括高病毒载量但肝功能正常的患者是否应该接受治疗以预防肝细胞癌（HCC）或肝病进展为肝硬化。另一个领域是定量乙型肝炎表面抗原（qHBsAg）是否可用于更好地描述 CHB 阶段和预测预后。最后，qHBsAg 在干扰素和核苷类似物等抗病毒治疗患者管理中的应用可以改善管理实践。